Rheumatology
News
Case series: Ustekinumab for psoriasis helps skin, hurts joints
Key clinical point: Increasing evidence suggests that ustekinumab is associated with discordant joint and skin responses. Major finding: Five of...
News
Framingham score underestimates CVD risk in psoriatic arthritis patients
Key clinical point: The Framingham Risk Score may not be applicable for estimating CVD risk in psoriatic arthritis patients. Major finding: The 10...
News
Lowest SLE survival rates found in black and Native American patients
Key clinical point: The findings confirm prior reports of racial variations in lupus prognosis.
News
Adalimumab effective in nonpsoriatic peripheral spondyloarthritis
Key clinical point: Patients with active nonpsoriatic peripheral spondyloarthritis who have not responded to treatment with NSAIDs might consider...
News
Reducing abatacept feasible for poor-prognosis early RA patients
Key clinical point: Patients with poor-prognosis early rheumatoid arthritis and DAS28-ESR of less than 2.6 after at least 1 year on abatacept (10...
News
Antibody elimination may mark radiographic outcomes in RA
Key clinical point: Early disappearance of anti-cVim antibodies can lead to better radiological outcomes in patients in the early stages of...
News
Intra-articular better than oral therapies for knee OA?
Key clinical point: Intra-articular treatments appear more effective than oral therapies for knee OA, but that may be due their greater placebo...
Applied Evidence
Antinuclear antibodies: When to test and how to interpret findings
Order ANA assays only when clinical features suggest a connective tissue disorder. Let ANA immunofluorescent patterns direct additional testing...
Photo Rounds
Inguinal area rash
News
Number, not level, of positive antibodies predicts mortality in early RA
Key clinical point: Dual rheumatoid factor and anti-citrullinated protein antibody positivity may be better than antibody levels for predicting...
News
IVIG may be worthwhile in treatment of refractory active diffuse scleroderma
Key clinical point: IVIG may be worth trying as an adjunctive therapy for active dcSSc in patients failing other therapies. Major finding: The...